Astrantus’s Vertex Pharmaceuticals VRTX Stock Holding History

Astrantus’s Portfolio VRTX Stock Details VRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q1	–	Sell	-6,300	Closed	-$1.38M	–	299
2021 Q4	$1.38M	Buy	+6,300	New	+$1.23M	1.03%	9

Other funds holding VRTX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Capital World Investors Los Angeles, California $846B AUM 46.74% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $302B AUM 26.44% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return

Loomis, Sayles & Company Boston, Massachusetts $79.8B AUM 16.05% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

ClearBridge Investments New York $121B AUM 27.52% 1-Year Est. Return

Astrantus's VRTX Position: Q1 2022 in Review

Astrantus sold out of Vertex Pharmaceuticals (VRTX) in Q1 2022, closing a stake of 6,300 shares — an estimated $1.38M sold.

Astrantus first reported a position in VRTX in Q4 2021 and held it in 1 quarter. The position peaked at $1.38M in Q4 2021. 1,073 funds tracked by Wall St. Rank hold VRTX as of Q1 2022.

Astrantus reported no remaining Vertex Pharmaceuticals position as of Q1 2022 after selling out during the quarter.
Astrantus sold 6,300 Vertex Pharmaceuticals shares in Q1 2022, an estimated $1.38M.
Astrantus first reported a position in Vertex Pharmaceuticals in Q4 2021 and held it in 1 quarter.
Astrantus's Vertex Pharmaceuticals position peaked at $1.38M in Q4 2021.
1,073 funds tracked by Wall St. Rank held Vertex Pharmaceuticals as of Q1 2022.

Based on Astrantus's 13F filing for Q1 2022, filed 11 May 2022.